Target：Group VI iPLA2

Fields：Glycerophospholipid metabolism;Ether lipid metabolism;Arachidonic acid metabolism;Linoleic acid metabolism;alpha-Linolenic acid metabolism;Metabolic pathways;Ras signaling pathway;Vascular smooth muscle contraction;Fc gamma R-mediated phagocytosis;Inflammatory mediator regulation of TRP channels

Gene Name：PLA2G6

Protein Name：85/88 kDa calcium-independent phospholipase A2

Human Gene Id：8398

Human Swiss Prot No：O60733

Mouse Gene Id：53357

Mouse Swiss Prot No：P97819

Rat Gene Id：360426

Rat Swiss Prot No：P97570

Immunogen：Synthesized peptide derived from the Internal region of human Group VI iPLA2.

Specificity：Group VI iPLA2 Polyclonal Antibody detects endogenous levels of Group VI iPLA2 protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500 - 1:2000. ELISA: 1:5000. Not yet tested in other applications.

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：PLA2G6;PLPLA9;85/88 kDa calcium-independent phospholipase A2;CaI-PLA2;Group VI phospholipase A2;GVI PLA2;Intracellular membrane-associated calcium-independent phospholipase A2 beta;iPLA2-beta;Patatin-like phospholipase domain-contai

Observed Band(KD)：90kD

Background： The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010],

Function：catalytic activity:Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate.,disease:Defects in PLA2G6 are a cause of neurodegeneration with brain iron accumulation (NBIA) [MIM:610217]. NBIA comprises a clinically and genetically heterogeneous group of disorders with high basal ganglia iron.,disease:Defects in PLA2G6 are the cause of infantile neuroaxonal dystrophy 1 (INAD1) [MIM:256600]; also known as Seitelberger disease. Infantile neuroaxonal dystrophy (INAD) is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years.,disease:Defects in PLA2G6 are the cause of Karak syndrome [MIM:608395]. Karak syndrome is a neurologic disease characterized by early-onset progressive cerebellar ataxia, dystonia, spasticity, intellectual and features c

Subcellular Location：Cytoplasm . Cell membrane . Mitochondrion . Cell projection, pseudopodium . Recruited to the membrane-enriched pseudopods upon MCP1/CCL2 stimulation in monocytes. .

Expression：Four different transcripts were found to be expressed in a distinct tissue distribution.